Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02464891
Other study ID # CL006_168
Secondary ID 2014-004261-24
Status Terminated
Phase Phase 2
First received May 26, 2015
Last updated November 13, 2017
Start date June 4, 2015
Est. completion date July 13, 2017

Study information

Verified date November 2017
Source Mario Negri Institute for Pharmacological Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect of CCX168, a C5aR Antagonist, Oral Administration on Ex Vivo Thrombus Formation and Disease Activity in ten patients with diagnosis of Atypical Hemolytic Uremic Syndrome with or without genetic abnormalities in the complement system or thrombomodulin, on stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months.


Description:

Inherited defects that determine uncontrolled activation of the alternative complement pathway have been well documented in atypical Hemolytic Uremic Syndrome (aHUS) patients. Research in recent years has identified more than 120 different mutations, accounting for around 40%-60% of cases, in the genes encoding complement factor H (CFH), membrane cofactor protein (MCP), complement factor I (CFI), C3, complement factor B (CFB), and thrombomodulin (THBD). A therapeutic approach could be the administration of molecules that pharmacologically target complement activation, which is the primary common pathogenic mechanism in all genetic forms of aHUS. Eculizumab has been successfully used as prophylaxis of aHUS recurrences in subjects with plasma dependent or plasma resistant disease or in renal transplant recipients at high risk of recurrence due to CFH, CFI, or C3 complement gene mutations. However the drug must be administered chronically and drug spacing or discontinuance was associated with disease recurrence in the graft. The C5aR receptor antagonist CCX168 could present an appealing alternative to eculizumab for post-transplant prophylaxis of aHUS recurrences since it is orally administrable with lower cost of goods. In addition, CCX168 is theoretically associated with lower risk of infections than eculizumab since the former does not target C5b and leaves the terminal complement pathway intact.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date July 13, 2017
Est. primary completion date July 13, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >18 years;

- Diagnosis of aHUS with or without identified genetic abnormalities in the complement system or thrombomodulin;

- Stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months;

- Written informed consent.

Exclusion Criteria:

- Women of childbearing potential or women who are breastfeeding;

- Shiga toxin-associated HUS or secondary forms of thrombotic microangiopathy;

- ADAMTS13 activity <10 % or circulating anti ADAMTS13 autoantibodies consistent with the diagnosis of thrombotic thrombocytopenic purpura;

- Need for specific intervention with plasma therapy and/or complement inhibitors as deemed clinically appropriate;

- Plasma therapy or treatment with complement inhibitors or antiplatelet and antithrombotic agents over the last two weeks;

- Liver function impairment (serum liver enzymes or bilirubin levels >3 x upper limit of normal);

- Neutrophil count < 2000/µL or lymphocyte count < 1000/µL;

- Infection requiring antibiotic treatment within the previous 4 weeks prior to screening;

- Participated in any clinical study of an investigational product within 30 days prior to screening or within 5 half-lives after taking the last dose;

- History or presence of any medical condition or disease which, in the opinion of the Investigator may place the subject at unacceptable risk for study participation;

- Inability to understand the potential risks and benefits of the study;

- Legal incapacity.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CCX168


Locations

Country Name City State
Italy A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò Bergamo

Sponsors (2)

Lead Sponsor Collaborator
Mario Negri Institute for Pharmacological Research ChemoCentryx

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ex vivo thrombogenesis. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Complement component 3 serum levels. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Complement component 4 serum levels. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Complement component 5 serum levels. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Complement Factor H. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Complement component 5a. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Soluble thrombomodulin. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Fibrin split products.. Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
Secondary Ex vivo C5b-9 deposition on microvascular endothelial cells At baseline.
Secondary Changes in pre-dialysis and intradialytic blood pressure. The participants will be followed for the duration of the study up to 21 days.
Secondary Changes in heart rate. The participants will be followed for the duration of the study up to 21 days.
Secondary Safety and tolerability parameters including serious and non serious events The participants will be followed for the duration of the study up to 21 days.
Secondary Patient health-related quality of life as measured by administration of EQ-5D-5L questionnaire. Changes from baseline at 14 and 21 day.
Secondary Characterization of CCX168 pharmacokinetic profile after oral administration by determining by maximum plasma concentration, time of maximum plasma concentration and area under the plasma concentration-time curve from time 0 to hour 6 Changes from Baseline at 4,9,11 and 15 day.
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Withdrawn NCT03303313 - A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Phase 2
Recruiting NCT04861259 - A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Phase 3
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Terminated NCT02614898 - Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
Completed NCT02574403 - Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Phase 4
Recruiting NCT04958265 - A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Phase 3
Recruiting NCT05795140 - Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Phase 3
Completed NCT00844545 - Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Phase 2
Completed NCT00844844 - Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Phase 2
Terminated NCT01522170 - aHUS Observational Long Term Follow-Up N/A
Withdrawn NCT02626663 - The Role of Microparticles as a Biomarker
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT00844428 - Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Phase 2
Completed NCT00838513 - Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Phase 2
Withdrawn NCT03999840 - Eculizumab to Cemdisiran Switch in aHUS Phase 2
Recruiting NCT04889430 - Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Phase 3
Recruiting NCT05935215 - Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Phase 3
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A